Duccio Volterrani, Paola Anna Erba, Ignasi Carrió, H. William Strauss, Giuliano Mariani. Nuclear Medicine Textbook Methodology and Clinical Application, 2 Volumes. Springer Nature Switzerland AG 2019, ISBN 978-3-319-95563-6

2019 ◽  
Vol 47 (1) ◽  
pp. 2-3
Author(s):  
Luigi Mansi
Keyword(s):  
Nuclear Medicine ◽  
Clinical Application

scholarly journals Applications of Radiolabelled Curcumin and Its Derivatives in Medicinal Chemistry

2021 ◽  
Vol 22 (14) ◽  
pp. 7410
Author(s):  
Matteo Mari ◽  
Debora Carrozza ◽  
Erika Ferrari ◽  
Mattia Asti
Keyword(s):  
Nuclear Medicine ◽  
Early Diagnosis ◽  
Clinical Application ◽  
Medicinal Chemistry ◽  
Biological Properties ◽  
Present Review ◽  
Chemical Modifications ◽  
Technetium 99M ◽  
Curcumin Derivatives ◽  
Gallium 68

Curcumin is a natural occurring molecule that has aroused much interest among researchers over the years due to its pleiotropic set of biological properties. In the nuclear medicine field, radiolabelled curcumin and curcumin derivatives have been studied as potential radiotracers for the early diagnosis of Alzheimer’s disease and cancer. In the present review, the synthetic pathways, labelling methods and the preclinical investigations involving these radioactive compounds are treated. The studies entailed chemical modifications for enhancing curcumin stability, as well as its functionalisation for the labelling with several radiohalogens or metal radionuclides (fluorine-18, technetium-99m, gallium-68, etc.). Although some drawbacks have yet to be addressed, and none of the radiolabelled curcuminoids have so far achieved clinical application, the studies performed hitherto provide useful insights and lay the foundation for further developments.

scholarly journals VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)

2016 ◽  
Vol 49 (2) ◽  
pp. 437-447 ◽  
Author(s):  
Samanta Taurone ◽  
Filippo Galli ◽  
Alberto Signore ◽  
Enzo Agostinelli ◽  
Rudi A.J.O. Dierckx ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Clinical Application ◽  
Future Perspectives

Possibilities of Software Phantoms for Quality Control of KBS in Nuclear Medicine

1992 ◽  
Vol 31 (02) ◽  
pp. 126-134 ◽  
Author(s):  
K. Kotzke ◽  
D.-P. Pretschner
Keyword(s):  
Quality Control ◽  
Nuclear Medicine ◽  
Clinical Application ◽  
Test Data ◽  
Real Data ◽  
Analysis Data ◽  
Basic Requirement ◽  
Knowledge Based System ◽  
Knowledge Based ◽  
Large Numbers

Abstract:The assessment of the results of a “knowledge-based system” (KBS) for quality control is a basic requirement for clinical application: Large numbers of test studies are necessary in order to cover as widely as possible the spectrum of cases to be analyzed by the KBS. The use of original patient data as test data is one possibility, but real data are provided unevenly. This is due to the set of characteristics which are relevant to the analysis. Data are available in a limited quantity only. This implies a remaining set of unvalidated cases which are not represented in the data pool. The software phantom is an approach towards systematically guided validation. It permits the generation of test data adjusted to the demands of the validation.

scholarly journals ANTISENSE OLIGONUCLEOTIDES AND RADIONUCLIDES – PERSPECTIVES

2021 ◽  
pp. 17-24
Author(s):  
Katya Popova ◽  
Maria Mincheva ◽  
Maria Yavahchova ◽  
Nikolay Goutev ◽  
Dimitar Tonev
Keyword(s):  
Nuclear Medicine ◽  
Clinical Application ◽  
Targeted Therapies ◽  
In Vivo Imaging ◽  
Antisense Oligonucleotides ◽  
Mechanisms Of Action ◽  
New Therapies ◽  
Advantages And Disadvantages ◽  
The Past

Over the past decade, antisense technology has successfully established itself as an entirely innovative platform for research and creation of new therapies. Significant advances in the design of antisense oligonucleotides, as well as a deeper understanding of their mechanisms of action, have led to their successful clinical application in many RNA-targeted therapies. In addition, their potential for in vivo imaging by radiolabeling has been identified. Here are discussed the prospects for the use of antisense oligonucleotides in nuclear medicine and highlighted some of the advantages and disadvantages of labelling them with radionuclides.

Biochemie der Metallocene, II Organ-Verteilung und Thymus-Anreicherung von [103Ru]Cinnamoyl-ruthenocen / Biochemistry of Metallocenes, II. Organ-Distribution and Thymus Affinity of Cinnamoyl-[103Ru] Ruthenocene

1977 ◽  
Vol 32 (7-8) ◽  
pp. 473-481 ◽  
Author(s):  
M. Wenzel ◽  
R. Herken ◽  
W. Klose
Keyword(s):  
Nuclear Medicine ◽  
Clinical Application ◽  
Biochemical Properties ◽  
The Body ◽  
Organ Distribution ◽  
Side Chains ◽  
Excretion Rates

Abstract Metallocenes, labelled with 103Ru, are potential radiopharmaceuticals for use in nuclear medicine diagnosis. Ruthenocene derivatives with oxopropene side-chains were administered to mice and rats to study their biochemical properties. Excretion rates and organ distributions of 103RuCl3 and Cinnamoyl-[103Ru] ruthenocene were very different. While 103RuCl3 was relatively evenly distributed in the body, the metallocene derivative was concentrated in liver, lungs and spleen after intravenous (i.v.) injection. After i.p. injection however a high thymus affinity was observed and autoradiography proved that the site of 103Ru accumulation was in thymocytes. The thymus affinity can be diminished by corticoid pretreatment and raised by inhibition of phagocytosis (BeSO4). The mechanism of accumulation in the thymus and a possible clinical application are discussed.

Sign in / Sign up

Export Citation Format

Share Document